Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study

Population Health Metrics

Jennifer Richmond-Bryant¹  Evan Coffman² 

[1] Environmental Media Assessment Group, National Center for Environmental Assessment, U.S. Environmental Protection Agency, Research Triangle Park NC 27711, USA;National Center for Environmental Assessment, U.S. Environmental Protection Agency, Oak Ridge Institute for Science and Education stationed at the Environmental Media Assessment Group, Research Triangle Park NC 27711, USA

关键词: NHANES;    Joint associations;    Metabolic syndrome;    Biomarkers;    Cardiovascular disease;   

Others  :  1139662
DOI  :  10.1186/s12963-015-0041-5

 received in 2014-09-10, accepted in 2015-02-18,  发布年份 2015

【 摘 要 】

Background

Metabolic syndrome (MetS) is the co-occurrence of several conditions that increase risk of chronic disease and mortality. Multivariate models for calculating risk of MetS-related diseases based on combinations of biomarkers are promising for future risk estimation if based on large population samples. Given biomarkers’ nonspecificity and commonality in predicting diseases, we hypothesized that unique combinations of the same clinical diagnostic criteria can be used in different multivariate models to develop more accurate individual and cumulative risk estimates for specific MetS-related diseases.

Methods

We utilized adult biomarker and cardiovascular disease (CVD) data from the National Health and Nutrition Examination Survey as part of a cross-sectional analysis. Serum C-reactive protein (CRP), glycohemoglobin, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, fasting glucose, and apolipoprotein-B were modeled. CVDs included congestive heart failure, coronary heart disease, angina, myocardial infarction, and stroke. Decile analysis for disease prevalence in each biomarker group and multivariate logistic regression for estimation of odds ratios were employed to measure the joint association between multiple biomarkers and CVD diagnoses.

Results

Of the biomarkers considered, glycohemoglobin, triglycerides, and CRP were consistently associated with the CVD outcomes of interest in decile analysis and were selected for the final models. Associations were overestimated when using single-marker models in comparison with full models; individual odds ratios decreased an average of 16.4% from the single-biomarker models to the joint association models for CRP, 6.6% for triglycerides, and 1.4% for glycohemoglobin. However, joint associations were stronger than any single-marker estimate. Additionally, reduced models produced unique combinations of biomarkers for specific CVD outcomes.

Conclusion

The reduced joint association modeling results suggest that unique combinations of biomarkers with their related measure of association can be used to produce more accurate cumulative risk estimates for each CVD. Additionally, our results indicate that the use of multiple biomarkers in a single multivariate model may provide increased accuracy of individual biomarker association estimates by controlling for statistical artifacts and spurious relationships due to co-biomarker confounding.

【 授权许可】

   
2015 Coffman and Richmond-Bryant; licensee BioMed Central.

【 参考文献 】

• [1]Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S: Prevalence and trends of metabolic syndrome in the adult U.S. population. J Am Coll Cardiol 2013 1999, 62(8):697-703.
• [2]Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112(20):3066-3072.
• [3]Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: report of the national heart, lung, and blood institute/american heart association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004, 24(2):e13-18.
• [4]Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 2002, 287(3):356-359.
• [5]Wilson PW, Kannel WB, Silbershatz H, D’Agostino RB: Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999, 159(10):1104-1109.
• [6]Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342(12):836-843.
• [7]Anand IS, Florea VG, Fisher L: Surrogate end points in heart failure. J Am Coll Cardiol 2002, 39(9):1414-1421.
• [8]Koenig W: Cardiovascular biomarkers: added value with an integrated approach? Circulation 2007, 116(1):3-5.
• [9]Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
• [10]Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24(11):987-1003.
• [11]Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002, 105(3):310-315.
• [12]NHANES 1999–2000 [http://wwwn.cdc.gov/nchs/nhanes/search/nhanes99_00.aspx]
• [13]NHANES 2001–2002 [http://wwwn.cdc.gov/nchs/nhanes/search/nhanes01_02.aspx]
• [14]NHANES 2003–2004 [http://wwwn.cdc.gov/nchs/nhanes/search/nhanes03_04.aspx]
• [15]NHANES 2005–2006 [http://wwwn.cdc.gov/nchs/nhanes/search/nhanes05_06.aspx]
• [16]NHANES 2007–2008 [http://wwwn.cdc.gov/nchs/nhanes/search/nhanes07_08.aspx]
• [17]NHANES 2009–2010 [http://wwwn.cdc.gov/nchs/nhanes/search/nhanes09_10.aspx]
• [18]Curtin LR, Mohadjer LK, Dohrmann SM, Montaquila JM, Kruszan-Moran D, Mirel LB, et al. The National Health and Nutrition Examination Survey: Sample Design, 2007–2010. Vital and health statistics Series 2, Data evaluation and methods research. 2013(160):1–32
• [19]Curtin LR, Mohadjer LK, Dohrmann SM, Montaquila JM, Kruszan-Moran D, Mirel LB, et al. The National Health and Nutrition Examination Survey: Sample Design, 1999–2006. Vital and health statistics Series 2, Data evaluation and methods research 2012(155):1–39.
• [20]1999–2000 Lab Methods [http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/lab_methods_99_00.htm]
• [21]2001–2002 Lab Methods [http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/lab_methods_01_02.htm]
• [22]2003–2004 Lab Methods [http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/lab_methods_03_04.htm]
• [23]2005–2006 Lab Methods [http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/lab_methods_05_06.htm]
• [24]2007–2008 Lab Methods [http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/lab_methods_07_08.htm]
• [25]2009–2010 Lab Methods [http://www.cdc.gov/nchs/nhanes/nhanes2009-2010/lab_methods_09_10.htm]
• [26]Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszan-Moran D, Dohrmann SM, et al.: National health and nutrition examination survey: analytic guidelines, 1999–2010. Vital Health Stat 2 . Data evaluation and methods research 2013, 161:1-24.
• [27]Winquist A, Kirraine E, Klein M, Strickland M, Darrow L, Sarnat S, et al. Joint effects of ambient air pollutants on pediatric asthma emergency department visits in Atlanta, 1998–2004. Epidemiology 2014.
• [28]Levy JI: Is epidemiology the key to cumulative risk assessment? Risk Anal 2008, 28(6):1507-1513.
• [29]Kleinbaum D, Klein M. Logistic regression - a self learning text. In. Gail M, Krickeberg K, Samet J, Tsiatis A, Wong W, editors. Third edn. New York: Springer; 2010
• [30]Heeringa S, Brady WT, Berglund PA: Applied Survey Data Analysis. Taylor & Francis, Boca Raton; 2010.
• [31]Hosmer DW, Lemeshow S: Applied Logistic Regression. 2nd edition. John Wiley & Sons, New York; 2000.
• [32]Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143–3421.
• [33]Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107(3):363-369.
• [34]Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107(3):391-397.
• [35]Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP: C-reactive protein and myocardial infarction. J Clin Epidemiol 2002, 55(5):445-451.
• [36]Myint PK, Sinha S, Wareham NJ, Bingham SA, Luben RN, Welch AA, et al.: Glycated hemoglobin and risk of stroke in people without known diabetes in the european prospective investigation into cancer (EPIC)-Norfolk prospective population study: a threshold relationship? Stroke 2007, 38(2):271-275.
• [37]Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al.: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115(4):450-458.
• [38]Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al.: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23(12):1835-1839.
• [39]Ford ES, Ajani UA, Mokdad AH: The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005, 28(4):878-881.
• [40]Sarwar N, Sattar N: Triglycerides and coronary heart disease: have recent insights yielded conclusive answers? Curr Opin Lipidol 2009, 20(4):275-281.
• [41]Resnick HE, Howard BV: Diabetes and cardiovascular disease. Annu Rev Med 2002, 53:245-267.
• [42]Wingard DL, Barrett-Connor E: Heart Disease and Diabetes. In: Diabetes in America. 2nd edn. US Government Printing Offices, Washington DC; 1995.
• [43]Pearce N, Checkoway H, Kriebel D: Bias in occupational epidemiology studies. Occup Environ Med 2007, 64(8):562-568.
• [44]Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR: C-reactive protein and outcome after ischemic stroke. Stroke 1999, 30(5):981-985.
• [45]Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A, et al.: Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke 2009, 40(11):3526-3531.
• [46]Weir CJ, Murray GD, Dyker AG, Lees KR: Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ (Clinical research ed) 1997, 314(7090):1303-1306.
• [47]Wong ND, Wilson PW, Kannel WB: Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991, 115(9):687-693.
• [48]Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI: Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996, 17(9):1345-1349.